Intelligence Platform
Patents
Browse 218 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.
US 8211891
Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
granted patentUS 8188132
Linked dibenzimidazole derivatives
granted patentUS 8178531
Antiviral agents
granted patentUS 8163707
4β²-allene-substituted nucleoside derivatives
granted patentUS 8124584
Macrocyclic hepatitis C serine protease inhibitors
granted patentUS 8101567
Heteroaryl-containing tripeptide HCV serine protease inhibitors
granted patentUS 8101643
Benzimidazole derivatives
granted patentUS 8030307
Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 pr
granted patentUS 7910587
Quinoxalinyl dipeptide hepatitis C virus inhibitors
granted patentUS 7906513
Hydrazide-containing hepatitis C serine protease inhibitors
granted patentUS 7728148
Acyclic oximyl hepatitis C protease inhibitors
granted patentUS 7718612
Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
granted patentUS 7718769
Tri-peptide hepatitis C serine protease inhibitors
granted patentUS 7687459
Arylalkoxyl hepatitis C virus protease inhibitors
granted patentUS 7662779
Triazolyl macrocyclic hepatitis C serine protease inhibitors
granted patentUS 7635683
Quinoxalinyl tripeptide hepatitis C virus inhibitors
granted patentUS 7605126
Acylaminoheteroaryl hepatitis C virus protease inhibitors
granted patentUS 7601709
Macrocyclic hepatitis C serine protease inhibitors
granted patentUS 7582605
Phosphorus-containing hepatitis C serine protease inhibitors
granted patentUS 7566719
Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
granted patentUS 7468419
Cyclosporin derivatives for the treatment of immune disorders
granted patentUS 7419962
3,6-bicyclolides
granted patentUS 7384921
Polymorphic forms of 6-11 bicyclic ketolide derivatives
granted patentUS 7368452
Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
granted